Jazz Pharmaceuticals plc

Welcome to the Jazz Pharmaceuticals plc third quarter 2020 earnings conference call. Following an introduction from the company, we will open the call to questions. I will now turn the call over to Cathy Luttrell, head of investor relations at Jazz Pharmaceuticals.

Thank you, Sheena, and thanks to those of you joining our investor calls. Today we reported our third quarter 2020 financial results and updated our financial guidance for 2020. The press release and the slide presentation accompanying this call are available in the investor section of our website. On the call today are Bruce Cozadd, CEO, Renee Gala, CFO, Dan Swisher, President, and Rob Iannone, Executive Vice President, R&D. Joining for the Q&A session are Kim Sablich, Executive Vice President, General Manager of North America, Bill Jockelson, Neuroscience Therapeutic Head, Ann Borgman, Hematology and Oncology Therapeutic Head, Sam Pearce, Senior Vice President, Europe and International, Shawn Mendes, Senior Vice President, Strategy and Finance, and Larry Carter, Global Development Lead, Neuroscience. I'd like to remind you that today's call includes forward-looking statements such as those related to our future financial and operating results, and which involve risks and uncertainties that could cause actual events, performance, and results to differ materially. We encourage you to review statements contained in today's press release and our latest SEC disclosure docs, which identify certain factors that may cause the company's actual results to differ materially from those projected. We undertake no duty or obligation to update our forward-looking statements. On this call, we discuss non-GAAP financial measures. Reconciliation of GAAP to non-GAAP financial measures discussed on this call are included in today's press release and slide presentation available on our website. I'll now turn the call over to Bruce.

Good afternoon, everyone, and thank you for joining us. In the third quarter, we delivered strong financial and operational results that build on the significant progress we made during the first half of the year. We executed on our key objectives, positioning us to deliver significant value and long-term growth. Since mid-year, despite ongoing impacts from COVID-19, our team has worked diligently to advance our strategy and align with the goals and milestones we set for Jazz at the beginning of the year. Including five key product launches in 2020 and 2021. Our focus on transforming our business through execution across regulatory, commercial, and R&D operations has continued, and today we achieved another exciting milestone in our neuroscience franchise with our U.S. launch of Zywave for EDS and cataplexy in narcolepsy. We strongly believe, based on more than 15 years of engagement with sleep specialists and patients, that reducing the lifelong burden of high sodium intake is an important advance for Oxibate patients. We are working hard to optimize our patient and physician education initiatives to ensure that existing and new Oxibate patients fully understand this benefit. Additionally, last month we announced positive and compelling Thank you for joining us today. Thank you so much for joining us. and is the first approved therapy in second line setting in over 20 years, giving physicians an important new tool in the management of this disease. Our team is executing exceptionally well and I'm pleased that physicians have enthusiastically embraced Zepzelka's benefits and profile. Through flexibility, innovation and commitment, we remain on track to execute on our important objectives across product launches, and Pipeline Advancements through 2020 and 2021, with three launches already underway and two planned for next year. Our overarching priority is to develop and bring new life-changing medicines to patients in areas of high unmet need. To that end, this year ranks as one of the most productive in Jazz's history. I'm excited about the future. With continued innovation, our strong commercial franchises Thanks, Bruce.